DTIL - Precision BioSciences Inc Stock Price, Fair Value and News

11.16USD-0.35 (-3.04%)Delayed as of 18 Apr 2024, 02:08 pm ET

Market Summary

USD11.16-0.35

Delayedas of 18 Apr 2024, 02:08 pm

-3.04%

DTIL Alerts

JANUS HENDERSON GROUP PLC reported owning 8% of DTIL [2024-03-11]

DTIL Stock Price

View Fullscreen

DTIL RSI Chart

DTIL Valuation

Market Cap

79.6M

Price/Earnings (Trailing)

-1.3

Price/Sales (Trailing)

1.63

Price/Free Cashflow

-0.95

DTIL Price/Sales (Trailing)

DTIL Profitability

Return on Equity

-325.11%

Return on Assets

-38.38%

Free Cashflow Yield

-105.66%

DTIL Fundamentals

DTIL Revenue

Revenue (TTM)

48.7M

Rev. Growth (Yr)

-33.59%

Rev. Growth (Qtr)

-46.36%

DTIL Earnings

Earnings (TTM)

-61.3M

Earnings Growth (Yr)

42.82%

Earnings Growth (Qtr)

-101.62%

Breaking Down DTIL Revenue

52 Week Range

11.63

(Low)(High)

Last 7 days

-18%

Last 30 days

-1.4%

Last 90 days

2.3%

Trailing 12 Months

-57.5%

How does DTIL drawdown profile look like?

DTIL Financial Health

Current Ratio

2.73

Debt/Equity

1.18

Debt/Cashflow

-3.78

DTIL Investor Care

Shares Dilution (1Y)

84.70%

Diluted EPS (TTM)

-15.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	30.6M	46.5M	52.3M	48.7M
2022	102.5M	37.5M	20.8M	25.1M
2021	33.6M	101.4M	118.0M	115.5M
2020	23.8M	19.5M	22.0M	24.3M
2019	14.8M	18.3M	20.7M	22.2M
2018	0	0	0	10.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Precision BioSciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 23, 2024	smith j. jefferson	sold	-10,360	0.37	-28,000	chief research officer
Jan 22, 2024	scimeca dario	sold	-7,663	0.36	-21,287	general counsel and secretary
Jan 22, 2024	list alan	sold	-7,749	0.36	-21,526	chief medical officer
Jan 22, 2024	amoroso michael	sold	-49,460	0.36	-137,390	president and ceo
Jan 20, 2024	list alan	acquired	-	-	60,012	chief medical officer
Jan 20, 2024	amoroso michael	acquired	-	-	266,720	president and ceo
Jan 20, 2024	smith j. jefferson	acquired	-	-	75,015	chief research officer
Jan 20, 2024	scimeca dario	acquired	-	-	59,345	general counsel and secretary
Jan 20, 2024	kelly john alexander	acquired	-	-	116,690	chief financial officer
Nov 03, 2023	amoroso michael	sold	-50,010	0.4	-125,025	president and ceo

Which funds bought or sold DTIL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	Ameliora Wealth Management Ltd.	sold off	-100	-365	-	-%
Apr 16, 2024	Ameliora Wealth Management Ltd.	new	-	447	447	-%
Apr 16, 2024	TSFG, LLC	sold off	-100	-	-	-%
Apr 16, 2024	TOTH FINANCIAL ADVISORY CORP	new	-	1,356	1,356	-%
Apr 16, 2024	TSFG, LLC	new	-	-	-	-%
Apr 15, 2024	FIRST CITIZENS BANK & TRUST CO	sold off	-100	-31,025	-	-%
Apr 05, 2024	CWM, LLC	sold off	-100	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.31	133,746	1,735,490	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	108	198,603	360,402	-%
Feb 27, 2024	Beaird Harris Wealth Management, LLC	sold off	-100	-46.00	-	-%

Are Funds Buying or Selling DTIL?

Are funds buying DTIL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DTIL

No. of Funds

DTIL Alerts

JANUS HENDERSON GROUP PLC reported owning 8% of DTIL [2024-03-11]

Unveiling Precision BioSciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 18, 2024	aquilo capital management, llc	7.1%	466,767	SC 13G
Mar 14, 2024	perceptive advisors llc	7.9%	5e+05	SC 13G
Mar 11, 2024	janus henderson group plc	8.0%	511,108	SC 13G
Feb 14, 2024	great point partners llc	0%	0	SC 13G/A
Feb 09, 2024	capital world investors	4.2%	5,119,458	SC 13G/A
Feb 05, 2024	tang capital partners lp	5.2%	6,400,000	SC 13G
Feb 27, 2023	great point partners llc	7.30%	8,099,799	SC 13G
Feb 14, 2023	great point partners llc	3.43%	3,801,305	SC 13G/A
Feb 13, 2023	capital world investors	6.1%	6,715,043	SC 13G/A
Feb 09, 2023	vanguard group inc	3.94%	4,373,367	SC 13G/A

Recent SEC filings of Precision BioSciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	8-K	Current Report
Mar 27, 2024	10-K	Annual Report
Mar 27, 2024	8-K	Current Report
Mar 18, 2024	SC 13G	Major Ownership Report
Mar 14, 2024	SC 13G	Major Ownership Report
Mar 11, 2024	SC 13G	Major Ownership Report
Mar 04, 2024	424B5	Prospectus Filed
Mar 01, 2024	8-K	Current Report
Mar 01, 2024	FWP	Prospectus Filed
Feb 29, 2024	424B5	Prospectus Filed

Peers (Alternatives to Precision BioSciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.5B	6.8B	-0.79%	-27.48%	-8.38	5.77	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-1.45%	-27.97%	-41.56	10.01	76.23%	61.08%
BMRN	17.1B	2.4B	7.98%	-8.04%	101.85	7.06	15.42%	18.43%
INCY	11.8B	3.7B	-8.07%	-28.58%	19.8	3.2	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-14.74%	-41.61%	-10.96	14.6	425.83%	18.94%
BBIO	4.4B	-	-10.03%	65.15%	-6.72	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-3.97%	-4.38%	-13.8	12.2	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.12%	-12.78%	-46.22	3.9	40.45%	71.62%
ARWR	2.8B	240.7M	-19.94%	-25.89%	-9.4	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.9B	398.2M	-0.50%	-10.21%	26.41	4.74	85.90%	-14.05%
NVAX	544.4M	983.7M	-24.32%	-58.17%	-1	0.55	-50.36%	17.16%
CRBP	389.6M	881.7K	-10.79%	209.42%	-8.73	466.16	-77.61%	-5.33%
INO	258.5M	4.9M	3.17%	4.73%	-1.91	53.11	-54.97%	51.71%
IBIO	6.6M	2.1M	79.05%	74.07%	-0.24	2.14	-13.45%	66.37%

Precision BioSciences Inc News

Latest updates

Precision BioSciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-46.4%	7,038	13,120	19,789	8,780	10,598	7,363	3,820	3,317	6,339	24,036	68,805	16,349	8,846	7,363	1,078	6,998	6,522	4,865	5,389	5,462	4,940
Operating Expenses	-53.1%	11,944	25,483	31,776	33,244	12,024	22,039	33,374	30,652	37,063	35,578	47,173	35,091	32,326	33,407	33,886	34,494	28,383	26,843	29,260	24,956	21,045
S&GA Expenses	-11.4%	8,539	9,633	9,830	11,086	9,955	10,281	10,438	10,680	10,593	9,638	9,938	9,498	9,200	8,534	8,703	9,615	8,479	7,052	6,500	4,995	4,646
R&D Expenses	-78.5%	3,405	15,850	21,946	22,158	2,070	11,758	22,936	19,972	26,470	25,940	37,235	25,593	23,126	24,873	25,183	24,879	19,904	19,791	22,760	19,961	16,399
Interest Expenses	0.5%	579	576	553	522	486	405	178	42.00	53.00	55.00	24.00	-	-	-	-	-	-	-	-	182	-
Net Income	-101.6%	-16,289	-8,079	-11,891	-25,060	-28,488	-23,946	-31,035	-28,168	-22,290	-11,279	21,656	-18,689	-23,453	-26,016	-32,701	-26,836	-20,916	-20,742	-19,436	-31,783	-15,443
Net Income Margin	10.5%	-1.26*	-1.41*	-1.92*	-3.55*	-4.45*	-5.06*	-2.47*	-0.39*	-0.26*	-0.27*	-0.46*	-3.00*	-	-	-	-	-	-	-	-	-
Free Cashflow	63.5%	-8,423	-23,093	-21,134	-31,464	-21,843	29,186	-24,224	-28,872	-23,681	-23,905	-31,339	68,072	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-2.8%	160	164	182	205	238	272	297	181	211	227	230	262	150	169	184	214	235	260	272	167	139
Current Assets	-6.5%	136	146	148	169	199	225	248	134	162	183	188	219	106	123	137	167	194	220	237	137	116
Cash Equivalents	-4.5%	117	122	138	158	190	212	184	116	144	160	174	193	90.00	104	127	154	181	206	226	116	103
Net PPE	-27.5%	6.00	9.00	18.00	19.00	12.00	22.00	23.00	24.00	25.00	32.00	33.00	34.00	35.00	36.00	38.00	39.00	40.00	39.00	33.00	28.00	21.00
Liabilities	4.2%	141	135	148	164	178	187	194	112	120	126	130	203	106	105	99.00	99.00	97.00	105	98.00	156	99.00
Current Liabilities	-1.2%	50.00	51.00	56.00	47.00	60.00	61.00	54.00	29.00	36.00	36.00	36.00	64.00	43.00	42.00	34.00	24.00	27.00	24.00	16.00	71.00	14.00
Long Term Debt	-	-	-	-	22.00	22.00	22.00	22.00	2.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-35.1%	19.00	29.00	34.00	40.00	60.00	84.00	103	70.00	91.00	101	101	59.00	44.00	64.00	86.00	115	138	156	174	11.00	40.00
Retained Earnings	-3.4%	-489	-473	-465	-453	-428	-399	-375	-344	-316	-294	-283	-304	-286	-262	-236	-203	-177	-156	-135	-115	-84.19
Additional Paid-In Capital	1.2%	509	503	500	495	490	485	480	415	409	397	385	365	331	327	323	320	316	313	310	128	126
Shares Outstanding	8.0%	4.00	4.00	4.00	4.00	4.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	59.00	-	-	-	170	-	-	-	664	-	-	-	383	-	-	-	589	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	63.5%	-8,423	-23,093	-21,134	-31,464	-21,843	29,186	-24,224	-28,872	-23,681	-23,905	-31,339	68,072	-13,452	-22,223	-25,801	-25,910	-20,556	-13,977	-16,575	-19,907	-12,912
Share Based Compensation	-4.4%	2,969	3,105	3,874	4,092	4,536	5,133	5,138	4,390	4,435	4,551	3,896	3,632	3,854	3,709	3,118	3,105	2,621	2,491	2,279	1,549	1,756
Cashflow From Investing	-99.4%	42.00	7,564	-1,056	-721	-632	-1,090	-779	-818	-1,505	-1,483	-1,690	-1,125	-1,096	-1,047	-1,785	-1,103	-5,529	-5,918	-8,137	-5,082	-9,871
Cashflow From Financing	8417.6%	2,828	-34.00	1,852	741	-	-180	92,916	2,249	8,378	11,916	13,512	36,715	198	532	285	314	706	61.00	134,312	38,295	-1,592

DTIL Income Statement

2023-12-31

STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 48,727	$ 25,098
Operating expenses
Research and development	53,375	46,122
General and administrative	39,088	41,284
Total operating expenses	92,463	87,406
Operating Loss	(43,736)	(62,308)
Other income (expense), net:
Impairment charges		(10,844)
Loss on disposal of assets	(461)	(30)
Gain (loss) on changes in fair value	1,145	(510)
Loss from equity method investment	(4,931)	(1,579)
Interest expense	(2,230)	(1,111)
Interest income	7,686	3,473
Total other income (expense), net	1,209	(10,601)
Loss from continuing operations	(42,527)	(72,909)
Loss from discontinued operations (including gain on disposal of $8,446 during the year ended December 31, 2023)	(18,792)	(38,728)
Net loss	$ (61,319)	$ (111,637)
Net loss per share - basic	$ (15.96)	$ (38.1)
Net loss per share - diluted	$ (15.96)	$ (38.1)
Weighted average shares of common stock outstanding - basic	3,841,405	2,929,873
Weighted average shares of common stock outstanding - diluted	3,841,405	2,929,873

DTIL Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 116,678	$ 189,576
Accounts receivable	901	720
Prepaid expenses	5,977	6,025
Convertible note receivable	11,897
Other current assets	419	1,228
Assets held for sale	487
Current assets of discontinued operations		1,556
Total current assets	136,359	199,105
Property, equipment, and software—net	6,338	11,815
Intangible assets—net	400	731
Right-of-use assets—net	8,263	1,964
Investment in equity securities	3,206	2,576
Equity method investment		2,172
Note receivable—net	4,990	7,234
Other assets	225	226
Noncurrent assets of discontinued operations		12,346
Total assets	159,781	238,169
Current liabilities:
Accounts payable	2,968	653
Accrued compensation	4,978	5,104
Accrued research and development expenses	1,557	1,827
Deferred revenue	12,035	46,192
Lease liabilities	1,133	1,678
Loan payable-net	22,412
Other current liabilities	2,391	745
Current liabilities of discontinued operations	2,513	3,465
Total current liabilities	49,987	59,664
Deferred revenue	73,082	82,872
Lease liabilities	7,723	1,059
Long term debt—net		22,223
Other liabilities		201
Contract liabilities	10,000	10,000
Noncurrent liabilities of discontinued operations	128	1,717
Total liabilities	140,920	177,736
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.0001 par value- 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022; no shares issued and outstanding as of December 31, 2023 and December 31, 2022
Common stock; $0.000005 par value- 200,000,000 shares authorized, 4,191,053 shares issued and 4,164,038 shares outstanding as of December 31, 2023; 3,725,689 shares issued and 3,698,674 shares outstanding as of December 31, 2022	1	1
Additional paid-in capital	509,443	489,696
Accumulated deficit	(489,631)	(428,312)
Treasury stock	(952)	(952)
Total stockholders’ equity	18,861	60,433
Total liabilities and stockholders’ equity	$ 159,781	$ 238,169

About Precision BioSciences Inc

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

CEO	Mr. Michael Amoroso
WEBSITE	precisionbiosciences.com
INDUSTRY	Biotechnology
EMPLOYEES	192

Precision BioSciences Inc Frequently Asked Questions

What is the ticker symbol for Precision BioSciences Inc? What does DTIL stand for in stocks?

DTIL is the stock ticker symbol of Precision BioSciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Precision BioSciences Inc (DTIL)?

As of Wed Apr 17 2024, market cap of Precision BioSciences Inc is 79.61 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DTIL stock?

You can check DTIL's fair value in chart for subscribers.

What is the fair value of DTIL stock?

You can check DTIL's fair value in chart for subscribers. The fair value of Precision BioSciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Precision BioSciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DTIL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Precision BioSciences Inc a good stock to buy?

The fair value guage provides a quick view whether DTIL is over valued or under valued. Whether Precision BioSciences Inc is cheap or expensive depends on the assumptions which impact Precision BioSciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DTIL.

What is Precision BioSciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, DTIL's PE ratio (Price to Earnings) is -1.3 and Price to Sales (PS) ratio is 1.63. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DTIL PE ratio will change depending on the future growth rate expectations of investors.